Laboratory services provider Labcorp (NYSE:LH) announced on Thursday a collaboration with the US Food and Drug Administration (FDA) and pharmaceutical research services provider Charles River Laboratories International Inc (NYSE:CRL) to advance the science used to evaluate a medicine's abuse potential, or the likelihood that it could be abused.
This research aims to support safer drug development and more informed regulatory decisions.
The collaboration brings together complementary expertise from industry and government. Labcorp will contribute its experience conducting regulatory abuse potential studies, while FDA scientists will conduct data analysis and contribute regulatory science expertise. Together, the organisations aim to advance the science used to evaluate the risk that a medicine could be abused using harmonised behavioural economics methodology to quantify and rank abuse potential.
Understanding how medicines and emerging substances may be used outside controlled settings is critical to protecting public health and informing regulatory decision-making, Labcorp said. The collaboration aims to advance the science used to assess abuse-related risks and generate evidence that may help improve the prediction of real-world use patterns.
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lupin's Amifampridine Tablets approved by US FDA
Roche wins FDA clearance for customisable respiratory pathogen test
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Immunome secures EMA validation of varegacestat application for desmoid tumors
FDA approves Sun Pharma's ILUMYA for psoriatic arthritis
Celularity and Vesalius sign exclusive US peptide manufacturing agreement
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights